60 Degrees Pharmaceuticals, Inc. SXTP
We take great care to ensure that the data presented and summarized in this overview for 60 DEGREES PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SXTP
Top Purchases
Top Sells
About SXTP
Insider Transactions at SXTP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2024
|
Geoffrey S Dow President and CEO |
BUY
Open market or private purchase
|
Direct |
3,500
+14.51%
|
$0
$0.91 P/Share
|
|
Nov 20
2024
|
Geoffrey S Dow President and CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+5.52%
|
$0
$0.92 P/Share
|
|
Nov 19
2024
|
Geoffrey S Dow President and CEO |
BUY
Open market or private purchase
|
Direct |
2,500
+13.42%
|
$0
$0.9 P/Share
|
|
Aug 27
2024
|
Cheryl Xu Director |
BUY
Open market or private purchase
|
Direct |
5,000
+10.85%
|
$5,000
$1.7 P/Share
|
|
May 16
2024
|
Paul Field Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+22.22%
|
$0
$0.22 P/Share
|
|
May 16
2024
|
Tyrone Miller CFO |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+7.82%
|
$0
$0.22 P/Share
|
|
May 16
2024
|
Stephen Toovey Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+22.22%
|
$0
$0.22 P/Share
|
|
May 16
2024
|
Cheryl Xu Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+0.87%
|
$0
$0.22 P/Share
|
|
May 16
2024
|
Charles W Allen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+22.22%
|
$0
$0.22 P/Share
|
|
May 16
2024
|
Geoffrey S Dow President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+2.18%
|
$0
$0.22 P/Share
|
|
Apr 12
2024
|
Tyrone Miller CFO |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+27.04%
|
$0
$0.27 P/Share
|
|
Apr 12
2024
|
Geoffrey S Dow President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
68,000
+8.36%
|
$0
$0.27 P/Share
|
|
Feb 01
2024
|
Cheryl Xu Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+25.0%
|
-
|
|
Jan 31
2024
|
Cheryl Xu Director |
BUY
Open market or private purchase
|
Direct |
200,000
+32.0%
|
$0
$0.38 P/Share
|
|
Jan 31
2024
|
Geoffrey S Dow President and CEO |
BUY
Open market or private purchase
|
Direct |
25,974
+3.56%
|
$0
$0.38 P/Share
|
|
Jul 28
2023
|
Knight Therapeutics Inc |
SELL
Conversion of derivative security
|
Indirect |
2,162
-2.67%
|
-
|
|
Jul 28
2023
|
Knight Therapeutics Inc |
BUY
Conversion of derivative security
|
Indirect |
45,560
+3.8%
|
$182,240
$4.75 P/Share
|
Last 12 Months Summary
Buy / Acquisition
414K
Shares
From
8
Insiders
| Exercise of conversion of derivative security | 97K shares |
|---|---|
| Grant, award, or other acquisition | 79K shares |
| Open market or private purchase | 238K shares |
Sell / Disposition
0
Shares
From
0
Insiders